Navigation Links
PharmAthene Appoints Mitchel Sayare, Ph.D. to the Company's Board of Directors
Date:4/28/2010

ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced the appointment of Mitchel Sayare, Ph.D. to PharmAthene's Board of Directors, increasing the company's Board to nine members.

Dr. Sayare most recently served as Chairman and Chief Executive Officer of ImmunoGen, a publicly traded biotechnology company engaged in the research and development of antibody-based cancer therapeutics.  During his long and successful tenure with the company, he was responsible for leading a successful IPO for ImmunoGen and raising over $300 million of venture capital and public equity financing for the company.  During this time, Dr. Sayare also served as President of the 95%-owned ImmunoGen subsidiary, Apoptosis Technology, where he was responsible for managing operations for the organization.

Prior to joining ImmunoGen, Dr. Sayare served as Vice President, Development at Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer.  In this role he oversaw all research and development, corporate development, and investor relations responsibilities for the company.

Dr. Sayare earned his Ph.D. in biochemistry from the Temple University School of Medicine and his undergraduate degree from Ursinus College.

"We are very pleased to have Dr. Sayare join PharmAthene's Board of Directors," commented John Pappajohn, Chairman of the Board.  "Mitch's extensive experience in the biotechnology industry – he was the first employee at ImmunoGen, provides a vast network of contacts and experiences to draw upon to assist PharmAthene in achieving its objective of being the leading provider of medical countermeasures for the nation.  As a former Director of the Biotechnology Industry Organization (BIO), Mitch is well known and respected within the biotechnology industry, and will bring an important and valuable perspective to PharmAthene."

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
2. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
3. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
4. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
5. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
6. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
7. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
8. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
9. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
10. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
11. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of AxioMed’s ... disc production, company President, Jake Lubinski will be traveling to Germany on December ... in Cologne and Karlsruhe to discuss the benefits of a viscoelastic total disc ...
(Date:12/5/2016)... -- NxGen MDx announced today that it brought its NxGen Informed Prenatal ... able to improve customer service through shortened turnaround times and at the ... CEO of NxGen MDx. ... A decrease in turnaround times by 25% ... opportunities at the Grand Rapid headquarters. The NxGen Informed Prenatal ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension ... federally funded research and development is welcome news for the photonics community, say ... , As part of the National Defense Authorization Act (NDAA) compromise agreement finalized ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of ... lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland from ... disc in Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic ...
Breaking Biology Technology:
(Date:11/21/2016)... 2016   Neurotechnology , a provider of ... announced that the MegaMatcher On Card fingerprint matching ... the NIST Minutiae Interoperability Exchange (MINEX) III ... steps of the evaluation protocol. ... of fingerprint templates used to establish compliance of ...
(Date:11/16/2016)... SANTA CLARA, Calif. , Nov. 16, 2016 /PRNewswire/ ... company enhancing user experience and security for consumer ... provider for the financial and retail industry, today ... more secure and convenient way to authenticate users ... now uses Sensory,s TrulySecure™ software which ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
Breaking Biology News(10 mins):